医学
氟达拉滨
内科学
单中心
髓系白血病
不利影响
肿瘤科
威尼斯人
克拉屈滨
化疗
耐火材料(行星科学)
移植
入射(几何)
阿糖胞苷
米托蒽醌
髓样
回顾性队列研究
白血病
挽救疗法
外科
淋巴瘤
嘌呤类似物
干细胞
中性粒细胞减少症
多发性骨髓瘤
造血干细胞移植
作者
Jose Tinajero,Dat Ngo,Brian Lee,Hoim Kim,Brian J. Ball,Paul Koller,Idoroenyi Usua Amanam,Hoda Pourhassan,Haris Ali,Salman Otoukesh,Amandeep Salhotra,Amanda L. Blackmon,Karamjeet Sandhu
标识
DOI:10.1177/10781552251396885
摘要
ObjectiveIntensive chemotherapy combinations with venetoclax are being used more frequently for acute myeloid leukemia (AML). In May 2022, a critical shortage of fludarabine prompted cladribine substitution at several institutions in the United States. FLAG-Ida-Ven and CLIA-Ven are similar IC regimens using different purine analogues, potentially with different efficacy and toxicity. To describe the patient population, outcomes, and toxicities of patients receiving FLAG-Ida-Ven and CLIA-Ven.Data SourcesA retrospective analysis of patients over 18 years with AML who received FLAG-Ida-Ven or CLIA-Ven for relapsed/refractory AML (R/R AML) at the City of Hope between December 2020 and January 2023.Data SummaryThere were 31 patients who received FLAG-Ida-Ven; 8 patients received CLIA-Ven. Patients were identified using ICD-10 code for AML and documented administration of medications. Most patients included were male with de novo AML with ELN adverse risk AML. Median age was 53 years (20-78) for FLAG-Ida-Ven and 47.5 years (23-69) for CLIA-Ven. Prior exposure to venetoclax based therapy was common (61.3% vs 50%). The ORR (overall response rate) in FLAG-Ida-Ven and CLIA-Ven was 46.7% and 75%, of which 86% vs 83% were MRD negative, respectively. There were 42% (n = 13) and 50% (n = 4) of patients who were able to proceed to allogeneic stem cell transplant in the FLAG-Ida-Ven and CLIA-Ven with median time to transplant being 89 vs 132 days respectively.Regarding safety, CLIA-Ven had a higher incidence of grade 3 or 4 non-hematologic adverse events, 6% vs 50% respectively. Survival from therapy initiation at 6 months was 48.4% vs 75%.ConclusionConsistent with the literature, it appears that the activity between FLAG-Ida-Ven and CLIA-Ven are comparable, however FLAG-Ida-Ven may have a more tolerable safety profile.
科研通智能强力驱动
Strongly Powered by AbleSci AI